

ODN 21595

Cat. No.:	HY-150740	
CAS No.:	1964506-28-2	
Target:	Toll-like Receptor (TLR)	
Pathway:	Immunology/Inflammation	DNA, d(P-thio)(T-C-C-T-G-G-C-c ₇ G-G-G-G-A-A-G-T)
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY

Description	ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN- α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) ^[1] .								
In Vitro	<p>ODN 21595 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs^[1].</p> <p>ODN 21595 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human PBMCs^[1].</p> <p>ODN 21595 (0.1, 1, 10 μM; 24 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human B-cells^[1].</p> <p>ODN 21595 (1, 10 μM; 48 h) displays a lower stimulatory activity and reduces significantly the CpG-ODN 2006 (100 nM) or imiquimod (5 μg/ml)-induced expression of CD86 or HLA-DR in CD20⁺ B-cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>human PBMCs</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Showed no cytotoxic for human PBMCs.</td> </tr> </table>	Cell Line:	human PBMCs	Concentration:	0.01, 0.1, 1, 10 μ M	Incubation Time:	48 h	Result:	Showed no cytotoxic for human PBMCs.
Cell Line:	human PBMCs								
Concentration:	0.01, 0.1, 1, 10 μ M								
Incubation Time:	48 h								
Result:	Showed no cytotoxic for human PBMCs.								

REFERENCES

[1]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA